Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit

Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Stephen R. Miller has been named Senior Vice President and General Manager, Patient Testing.

"His contributions to the team will be invaluable as we continue to refine and implement our commercialization strategies, which are designed to optimize the many promising market opportunities addressed by our portfolio of products and services."
Mr. Miller brings over 22 years of experience in the diagnostics and biotechnology industries to Transgenomic, with a proven track record of commercializing molecular diagnostic tests on a global basis. Most recently, he provided commercial and strategic consultancy services to a variety of diagnostics companies, including Transgenomic. With expertise covering sales, marketing, and business development, Mr. Miller also brings in-depth experience in developing and implementing strategic commercialization and reimbursement plans.

"Steve's wealth of experience in commercializing and marketing innovative molecular diagnostic technologies, combined with strong planning and leadership skills, strengthen the leadership team at Transgenomic at an important time in our growth and development as a Company," said Paul Kinnon, President and Chief Executive Officer of Transgenomic. "His contributions to the team will be invaluable as we continue to refine and implement our commercialization strategies, which are designed to optimize the many promising market opportunities addressed by our portfolio of products and services."

"Transgenomic has a broad portfolio of innovative, medically important genetic tests and technologies," said Mr. Miller. "I look forward to being an integral part of the management team and to leveraging my commercial and business development expertise to maximize both Transgenomic's strategic partnership opportunities and commercial operations."

Previously, Mr. Miller was the Chief Commercial Officer of BG Medicine, Inc., where he was instrumental in the global launch of a novel cardiac biomarker, in addition to being responsible for global sales, marketing, business development, strategic alliances, reimbursement and international expansion initiatives. Mr. Miller joined BG Medicine in 2011 from Mira Dx, where he held the positions of President and Chief Commercial Officer. Mr. Miller was previously the Vice President of Sales and Marketing at Athena Diagnostics. Mr. Miller holds a B.A. from Miami University.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases. The Company has three complementary business units: Patient Testing, Biomarker Identification, and Genetic Assays and Platforms, which provide specialized diagnostic tests, contract research services for drug development, and equipment, reagents and other consumables for clinical and research applications in molecular testing and cytogenetics.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Contacts

Investor Contact:
Argot Partners
David Pitts, 212-600-1902
[email protected]
or
Company Contact:
Transgenomic, Inc.
Investor Relations, 402-452-5416
[email protected]

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.